序号 |
标题 |
次数 |
作者 |
发布时间 |
73981 |
Mal-PEG2-Val-Ala-PAB-PNP,含有马来酰亚胺(Mal)官能团、两个单元的聚乙二醇(PEG2)间隔物、缬氨酸(Val)和丙氨酸(Ala)的序列 |
73 |
WYQ |
2024-12-18 |
73982 |
Mal-PEG2-Val-Cit-PABA(CAS号:1662687-83-3) |
93 |
WYQ |
2024-12-18 |
73983 |
CAS号:1096584-62-1, Mal-Val-Cit-PAB-PNP |
70 |
WYQ |
2024-12-18 |
73984 |
Mal-amido-PEG2-Val-Cit-PAB-OH,马来酰亚胺-酰胺-二聚乙二醇-缬氨酸-瓜氨酸-PAB-羟基 |
69 |
WYQ |
2024-12-18 |
73985 |
CAS号:1949793-41-2 ,Mal-amido-PEG4-Val-Cit-PAB-OH |
79 |
WYQ |
2024-12-18 |
73986 |
DOTA-伊班膦酸 DOTA-IBA |
73 |
h |
2024-12-18 |
73987 |
FA-DOTA-PEG-PLGA 叶酸-DOTA-聚乙二醇-聚乳酸-羟基乙酸共聚物 |
82 |
h |
2024-12-18 |
73988 |
DOTA-泛素29-41 |
73 |
h |
2024-12-18 |
73989 |
cas:1226403-39-9,N-(2-(3,4-Difluorophenoxy)ethyl)-4-formylbenzamide |
76 |
kx |
2024-12-18 |
73990 |
Cu-64 DOTA-曲妥珠单抗 Cu-64-Herceptin |
120 |
h |
2024-12-18 |
73991 |
CAS号:2112738-13-1 ,Mal-amido-PEG2-Val-Cit-PAB-PNP |
79 |
WYQ |
2024-12-18 |
73992 |
CAS号:2055041-40-0 , Azido-PEG1-Val-Cit-PAB-OH |
91 |
WYQ |
2024-12-18 |
73993 |
cas:1226006-55-8,N-(2-(3-Ethoxyphenoxy)ethyl)-4-formylbenzamide, ADC试剂 |
67 |
kx |
2024-12-18 |
73994 |
DOTA-LTVSPWY 双功能螯合剂DOTA偶联肽LTVSPWY |
71 |
h |
2024-12-18 |
73995 |
CAS号:2055024-65-0 ,Azido-PEG3-Val-Cit-PAB-OH |
77 |
WYQ |
2024-12-18 |
73996 |
DOTA-CCK-66 大环DOTA偶联CCK2R靶向化合物CCK-66 |
174 |
h |
2024-12-18 |
73997 |
cas:1228153-04-5,4-Formyl-N-(2-(naphthalen-2-yloxy)ethyl)benzamide |
103 |
kx |
2024-12-18 |
73998 |
抗DOTA IgG-scFv BsAb anti-DOTA IgG-scFv BsAb |
117 |
h |
2024-12-18 |
73999 |
cas:1226217-30-6,4-Formyl-N-(2-(4-isopropylphenoxy)ethyl)benzamide |
81 |
kx |
2024-12-18 |
74000 |
DOTA-rL-A9肽 DOTA偶联核定位序列(NLS)-移植的her 2-受体亲和肽 |
96 |
h |
2024-12-18 |
74001 |
cas:796073-59-1,2,5-Dioxopyrrolidin-1-yl 4-(methyldisulfanyl)pentanoate |
71 |
kx |
2024-12-18 |
74002 |
DOTA-E[c(RGDFK)]2 双功能螯合剂偶联的RGD多肽E[c(RGDfK)]2 |
74 |
h |
2024-12-18 |
74003 |
DBCO-C4-Val-Cit-PABC-PNP,分子式:C46H49N7O10 |
80 |
WYQ |
2024-12-18 |
74004 |
DBCO-(PEG)3-VC-PAB-MMAE,CAS号:57103-68-1 |
54 |
WYQ |
2024-12-18 |
74005 |
cas:1134280-65-1,2,5-Dioxopyrrolidin-1-yl 3-((2,4-difluorobenzyl)oxy)propanoate |
78 |
kx |
2024-12-18 |
74006 |
DBCO-PEG3-acetic-Val-Cit-PAB(二苯并环辛炔) |
84 |
WYQ |
2024-12-18 |
74007 |
cas:1824718-79-7,SPDH, ADC试剂 |
85 |
kx |
2024-12-18 |
74008 |
cas:1232769-29-7,2,5-dioxopyrrolidin-1-yl 19-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-19-oxo-4,7,10,13,16-pentaoxanonadecan-1-oate |
86 |
kx |
2024-12-18 |
74009 |
Amino-PEG2-VG-N-Bis(PEG1-azide),氨基-二聚乙二醇-VG-N-双(一聚乙二醇-叠氮) |
125 |
WYQ |
2024-12-18 |
74010 |
Alkyne-Val-Cit-PAB-FAM,炔-VAL-CIT-PAB-FAM |
72 |
WYQ |
2024-12-18 |
74011 |
cas:1226218-43-4,4-Formyl-N-(2-(2,3,6-trimethylphenoxy)ethyl)benzamide |
67 |
kx |
2024-12-18 |
74012 |
双功能螫合剂DOTA偶联MAG3 DOTA-MAG3 |
105 |
h |
2024-12-18 |
74013 |
Alkyne-Val-Cit-PAB-PNP,炔-Val-Cit-PAB-PNP |
85 |
WYQ |
2024-12-18 |
74014 |
DOTA-MSH2 金属螯合剂DOTA偶联二聚体肽(MSH2) |
88 |
h |
2024-12-18 |
74015 |
cas:796073-64-8,(S)-2,5-Dioxopyrrolidin-1-yl 4-(methyldisulfanyl)pentanoate |
70 |
kx |
2024-12-18 |
74016 |
N,N-二乙基正辛硫基乙酰胺,(N,N-Diethyl-α-(OctlyThio)-Acetamide)简称DOTA |
69 |
h |
2024-12-18 |
74017 |
cas:437655-95-3,Fmoc-NH-PEG4-CH2COOH, 5,8,11,14-四氧杂-2-氮杂十六碳二酸 1-芴甲基酯 |
81 |
kx |
2024-12-18 |
74018 |
Val-Ala-PAB-OH |
103 |
zyl |
2024-12-18 |
74019 |
DOTA-Bz-Cys-RGD dimer 双功能螯合剂修饰Cys-RGD dimer |
80 |
h |
2024-12-18 |
74020 |
cas:874208-92-1,m-PEG7-NHS ester, ADC试剂 |
90 |
kx |
2024-12-18 |
74021 |
Boc-PEG4-Val-Ala-PAB-PNP |
85 |
zyl |
2024-12-18 |
74022 |
111 In-奥曲肽(Octreo Scan) |
311 |
h |
2024-12-18 |
74023 |
POSS-DOTA 大环配体DOTA偶联七异丁基-氨丙基六面体倍半硅氧烷POSS |
82 |
h |
2024-12-18 |
74024 |
cas:164332-88-1,N-Boc-PEG1-bromide, [2-(2-溴乙氧基)乙基]氨基甲酸叔丁酯 |
63 |
kx |
2024-12-18 |
74025 |
DOTA-Substance P DOTA-SP |
93 |
h |
2024-12-18 |